Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 329

1.

Utility of the CAT in the therapy assessment of COPD exacerbations in China.

Tu YH, Zhang Y, Fei GH.

BMC Pulm Med. 2014 Mar 11;14:42. doi: 10.1186/1471-2466-14-42.

2.

Is the COPD assessment test (CAT) effective in demonstrating the systemic inflammation and other components in COPD?

Sarioglu N, Hismiogullari AA, Bilen C, Erel F.

Rev Port Pneumol (2006). 2016 Jan-Feb;22(1):11-7. doi: 10.1016/j.rppnen.2015.08.007. Epub 2015 Oct 31.

3.

Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification.

Jones PW, Adamek L, Nadeau G, Banik N.

Eur Respir J. 2013 Sep;42(3):647-54. doi: 10.1183/09031936.00125612. Epub 2012 Dec 20.

4.

[Correlation among the levels of C-reactive protein and interleukin-18, quality of life, and lung function in patients with chronic obstructive pulmonary disease].

Long H, Luo H, Chen P, Li Y.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Nov;36(11):1090-6. doi: 10.3969/j.issn.1672-7347.2011.11.010. Chinese.

5.

Investigating sensitivity, specificity, and area under the curve of the Clinical COPD Questionnaire, COPD Assessment Test, and Modified Medical Research Council scale according to GOLD using St George's Respiratory Questionnaire cutoff 25 (and 20) as reference.

Tsiligianni IG, Alma HJ, de Jong C, Jelusic D, Wittmann M, Schuler M, Schultz K, Kollen BJ, van der Molen T, Kocks JW.

Int J Chron Obstruct Pulmon Dis. 2016 May 18;11:1045-52. doi: 10.2147/COPD.S99793. eCollection 2016.

6.

Minimum clinically important difference for the COPD Assessment Test: a prospective analysis.

Kon SS, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, Haselden BM, Polkey MI, Man WD.

Lancet Respir Med. 2014 Mar;2(3):195-203. doi: 10.1016/S2213-2600(14)70001-3. Epub 2014 Feb 4.

7.

The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis.

Martin AL, Marvel J, Fahrbach K, Cadarette SM, Wilcox TK, Donohue JF.

Respir Res. 2016 Apr 16;17:40. doi: 10.1186/s12931-016-0356-1. Review.

8.

Comparison of symptom and risk assessment methods among patients with chronic obstructive pulmonary disease.

Zhang R, Tan X, He Q, Chen Q, Gai J, Wei J, Wang Y.

Chin Med J (Engl). 2014;127(14):2594-8.

PMID:
25043073
9.

Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: a cross-sectional analyses.

Kim S, Oh J, Kim YI, Ban HJ, Kwon YS, Oh IJ, Kim KS, Kim YC, Lim SC.

BMC Pulm Med. 2013 Jun 3;13:35. doi: 10.1186/1471-2466-13-35.

10.

American translation, modification, and validation of the St. George's Respiratory Questionnaire.

Barr JT, Schumacher GE, Freeman S, LeMoine M, Bakst AW, Jones PW.

Clin Ther. 2000 Sep;22(9):1121-45.

PMID:
11048909
11.

Analysis of longitudinal changes in dyspnea of patients with chronic obstructive pulmonary disease: an observational study.

Oga T, Tsukino M, Hajiro T, Ikeda A, Nishimura K.

Respir Res. 2012 Sep 25;13:85. doi: 10.1186/1465-9921-13-85.

12.

Evaluation of the chronic obstructive pulmonary disease assessment test for measurement of health-related quality of life in patients with interstitial lung disease.

Nagata K, Tomii K, Otsuka K, Tachikawa R, Otsuka K, Takeshita J, Tanaka K, Matsumoto T, Monden K.

Respirology. 2012 Apr;17(3):506-12. doi: 10.1111/j.1440-1843.2012.02131.x.

PMID:
22257381
13.

[Validity and reliability of Turkish version of St. George's respiratory questionnaire].

Polatlı M, Yorgancıoğlu A, Aydemir Ö, Yılmaz Demirci N, Kırkıl G, Atış Naycı S, Köktürk N, Uysal A, Akdemir SE, Özgür ES, Günakan G.

Tuberk Toraks. 2013;61(2):81-7. Turkish.

14.

The COPD assessment test and St George's Respiratory Questionnaire: are they equivalent in subjects with COPD?

Morishita-Katsu M, Nishimura K, Taniguchi H, Kimura T, Kondoh Y, Kataoka K, Ogawa T, Watanabe F, Arizono S, Nishiyama O, Nakayasu K, Imaizumi K, Hasegawa Y.

Int J Chron Obstruct Pulmon Dis. 2016 Jul 7;11:1543-51. doi: 10.2147/COPD.S104947. eCollection 2016.

15.

Predictors of health status do not change over three-year periods and exacerbation makes difference in chronic obstructive pulmonary disease.

Ferrari R, Tanni SE, Caram LM, Naves CR, Godoy I.

Health Qual Life Outcomes. 2011 Dec 9;9:112. doi: 10.1186/1477-7525-9-112.

16.

GOLD 2011 disease severity classification in COPDGene: a prospective cohort study.

Han MK, Muellerova H, Curran-Everett D, Dransfield MT, Washko GR, Regan EA, Bowler RP, Beaty TH, Hokanson JE, Lynch DA, Jones PW, Anzueto A, Martinez FJ, Crapo JD, Silverman EK, Make BJ.

Lancet Respir Med. 2013 Mar;1(1):43-50. doi: 10.1016/S2213-2600(12)70044-9. Epub 2012 Sep 3.

17.

Impact of comorbidities on COPD-specific health-related quality of life.

Burgel PR, Escamilla R, Perez T, Carré P, Caillaud D, Chanez P, Pinet C, Jebrak G, Brinchault G, Court-Fortune I, Paillasseur JL, Roche N; INITIATIVES BPCO Scientific Committee.

Respir Med. 2013 Feb;107(2):233-41. doi: 10.1016/j.rmed.2012.10.002. Epub 2012 Oct 23.

19.
20.

Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences.

Ohno T, Wada S, Hanada S, Sawaguchi H, Muraki M, Tohda Y.

Int J Chron Obstruct Pulmon Dis. 2014 Jan 21;9:107-14. doi: 10.2147/COPD.S56777. eCollection 2014.

Supplemental Content

Support Center